One point is given for each of the characteristics below present in the patient, for a total score ranging from zero to seven |
Serum albumin <4 g/dL |
Hemoglobin <10.5 g/dL |
Male gender |
Age >45 years |
Stage IV disease |
White blood cell count ≥15,000/microL |
Absolute lymphocyte count <600/microL and/or <8 percent of the total white blood cell count |
When applied to an initial group of 5141 patients with advanced Hodgkin lymphoma treated prior to 1992 with combination chemotherapy with or without radiation therapy, five-year overall survival (OS) and freedom from progression (FFP) rates according to score were as follows[1]: |
Score | Five-year FFP, percent | Five-year OS, percent |
0 | 84 | 89 |
1 | 77 | 90 |
2 | 67 | 81 |
3 | 60 | 78 |
4 | 51 | 61 |
5 or more | 42 | 56 |
When applied to 740 patients with advanced Hodgkin lymphoma treated with curative intent with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) from 1980 to 2010, five-year OS and FFP rates according to score were as follows[2]: |
Score | Five-year FFP, percent | Five-year OS, percent |
0 | 88 | 98 |
1 | 84 | 97 |
2 | 80 | 91 |
3 | 74 | 88 |
4 | 67 | 85 |
5 or more | 62 | 67 |